PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -11.2% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +8 | 59.00M | $4.80B | +13 | −7 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | — |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | — |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | — |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | — | — |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | — | −2 |
| Q2 2024 | 13 | — | 14.28M | $436.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.79M | -39.4% | $216.09M | 0.0% | ▼ Trim | 3 | SEC ↗ ×7 |
| 2 | State Street Global Advisors ✦ (passive) | 2.71M | — | $122.24M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.80M | -0.1% | $81.14M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | D. E. Shaw & Co. ✦ | 1.54M | +8.7% | $69.62M | 0.1% | ▲ Add | 3 | SEC ↗ ×3 |
| 5 | Point72 Asset Management ✦ | 1.44M | +150.6% | $65.15M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 653.10K | +21.4% | $29.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 509.20K | -9.0% | $22.99M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 458.01K | +91.5% | $20.67M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 309.42K | +41.0% | $13.97M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 306.76K | +22.7% | $13.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 173.35K | -45.4% | $7.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 157.35K | -17.0% | $7.10M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 348 holders, 95.15M shares, $6.33B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 53 sh · $3,389
Director · 2.45K sh · $155,091
Officer · 435 sh · $27,910
Officer · 1.64K sh · $104,881
Director · 376 sh · $25,737
Director · 9.62K sh · $652,796
Director · 2.99K sh · $199,341
Director · 7.01K sh · $471,854
Director · 10.00K sh · $673,400
Director · 9.43K sh · $639,124
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology